PLoS ONEplosplosonePLOS ONE1932-6203Public Library of ScienceSan Francisco, CA USA10.1371/journal.pone.0273387PONE-D-22-22318CorrectionCorrection: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysisSchadFriedemannThronickeAnjaSteeleMegan L.MerkleAntjeMatthesBurkhardGrahChristianMatthesHarald16820222022178e02733872022Schad et alThis is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis
The following information is missing from the Competing Interests statement:
Dr. Harald Matthes is a member of the board of directors at Weleda AG, a company that until 2016 distributed Iscador, a mistletoe preparation. In addition, Dr. Harald Matthes is a member of the board of the Hufelandgesellschaft e. V. in Germany; President of the DAHN (German Academy for Homeopathy and Naturopathy); and medical director and managing director of Gemeinschaftskrankenhaus Havelhöhe, a hospital for anthroposophic medicine. Dr. Harald Matthes is also a recipient on an endowed professorship from Charité in Berlin on Integrative and Anthroposophical Medicine. These competing interests do not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
ReferenceSchadF, ThronickeA, SteeleML, MerkleA, MatthesB, GrahC, et al. (2018) Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS ONE13(8): e0203058. https://doi.org/10.1371/journal.pone.020305830148853